Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells

Liver International

Volumn 33, Issue 7, 2013, Pages 1029-1038

  Dubreuil, Marta ^a   Ruiz Gaspà, Silvia ^a   Guañabens, Nuria ^a   Peris, Pilar ^a   Álvarez, Luisa ^a   Monegal, Ana ^a   Combalia, Andrés ^a   Parés, Albert ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bile acids; Bone mass; Cholestasis; Osteoporosis; Primary biliary cirrhosis

Indexed keywords

BILIRUBIN; CHOLIC ACID; HUMAN ALBUMIN; LITHOCHOLIC ACID; URSODEOXYCHOLIC ACID;

ARTICLE; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION (PARAMETERS); HUMAN; HUMAN CELL; HUMAN TISSUE; NORMAL HUMAN; OSTEOBLAST;

BILE ACIDS; BONE MASS; CHOLESTASIS; OSTEOPOROSIS; PRIMARY BILIARY CIRRHOSIS;

BILIRUBIN; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; CHOLESTASIS; HUMANS; JAUNDICE; LITHOCHOLIC ACID; OSTEOBLASTS; OSTEOPOROSIS; STATISTICS, NONPARAMETRIC; URSODEOXYCHOLIC ACID;

EID: 84880167050     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12153     Document Type: Article

References (32)

1. Guañabens N, Parés A, Mariñoso L, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990; 85: 1356-62.
2. Menon KV, Angulo P, Weston S, et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001; 35: 316-23.
3. Guañabens N, Parés A, Ros I, et al. Severity of cholestasis and advanced histological stage, but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005; 42: 573-7.
4. Guichelaar MM, Kendall R, Malinchoc M, et al. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006; 12: 1390-402.
5. Parés A, Guañabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis 2008; 12: 407-24.
6. Ruiz-Gaspà S, Guañabens N, Enjuanes A, et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest 2010; 40: 25-34.
7. Janes CH, Dickson ER, Okazaki R, et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995; 95: 2581-6.
8. Ruiz-Gaspà S, Martinez-Ferrer A, Guañabens N, et al. Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases. Hepatology 2011; 54: 2104-13.
9. Lee YM, Kaplan MM. The natural history of PBC: has it changed? Semin Liver Dis 2005; 25: 321-6.
10. Parés A, Caballeria L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715-20.
11. Beuers U, Boberg KM, Chapman RW, et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
12. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-14.
13. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36: 525-31.
14. Lindor KD, Janes CH, Crippin JS, et al. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995; 21: 389-92.
15. Verma A, Maxwell JD, Ang L, et al. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis. Osteoporos Int 2002; 13: 677-82.
16. Guañabens N, Cerdá D, Monegal A, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010; 138: 2348-56.
17. Benz C, Angermuller S, Tox U, et al. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis and cytolysis in rat hepatocytes. J Hepatol 1998; 28: 99-106.
18. Qiao L, Yacoub A, Studer E, et al. Inhibition of the mitogen activated protein kinase (MAPK) and phosphatidyl inositol 3-kinase (PI3K) pathways enhances ursodeoxycholic acid-induced apoptosis in primary rodent hepatocytes. Hepatology 2002; 35: 779-89.
19. Im E, Martinez JD. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signalling in human colon cancer cells. J Nutr 2004; 134: 483-6.
20. Castro RE, Sola S, Ramalho RM, et al. The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons. J Pharmacol Exp Ther 2004; 311: 845-52.
21. Rajesh KG, Suzuki R, Maeda H, et al. Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K/Akt dependent pathway. J Mol Cell Cardiol 2005; 39: 766-76.
22. Robey PG, Termine JD. Human bone cells in vitro. Calcif Tissue Int 1985; 37: 453-60.
23. Hernandez MV, Guañabens N, Alvarez L, et al. Immunocytochemical evidence on the effects of glucocorticoids on type I collagen synthesis in human osteoblastic cells. Calcif Tissue Int 2004; 74: 284-93.
24. Fedde KN. Human osteosarcoma cells spontaneously release matrix-vesicle-like structures with the capacity to mineralize. Bone Miner 1992; 17: 145-51.
25. Hale LV, Ma YF, Santerre RF. Semi-quantitative fluorescence analysis of calcein binding as a measurement of in vitro mineralization. Calcif Tissue Int 2000; 67: 80-4.
26. Hausser HJ, Brenner RE. Low-doses and high-doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro. J Cell Biochem 2004; 91: 1062-73.
27. Amaral JD, Viana RJ, Ramalho RM, et al. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 2009; 50: 1721-34.
28. Miura T, Ouchida R, Yoshikawa N, et al. Functional modulation of the glucocorticoid receptor and suppression of NF- kB-dependent transcription by ursodeoxycholic acid. J Biol Chem 2001; 276: 47371-8.
29. Fernandes A, Vaz AR, Falcão AS, et al. Glycoursodeoxycholic acid and interleukin-10 modulate the reactivity of rat cortical astrocytes to unconjugated bilirubin. J Neuropathol Exp Neurol 2007; 66: 789-98.
30. Poupon RE, Chrétien Y, Poupon R, et al. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993; 17: 599-604.
31. Sinakos E, Marschall H.-U., Kowdley KV, et al. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology 2010; 52: 197-203.
32. Rust C, Sauter GH, Oswald M, et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest 2000; 30: 135-9.